GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoCellular Therapeutics Ltd (FRA:KOL1) » Definitions » Cash Receipts from Loans

ImmunoCellular Therapeutics (FRA:KOL1) Cash Receipts from Loans


View and export this data going back to . Start your Free Trial

What is ImmunoCellular Therapeutics Cash Receipts from Loans?

Cash Receipts from Loans only applicable to companies reporting Cash Flow from Operations in direct method.


ImmunoCellular Therapeutics (FRA:KOL1) Business Description

Traded in Other Exchanges
N/A
Address
136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.